---
markmap:
  initialExpandLevel: 3
---

# HIGH RISK For Breast Cancer
## No Germline mutation
### IBIS Residual Lifetime Risk >=20% and 10-year >= 5%
#### Annual MMG and MRI (Minimum age 30 and 25 respectively)
#### Chemoprevention with AI or Tamoxifen (20mg vs babytam) 
### IBIS Residual Lifetime Risk >=20% and 10-year < 5%
#### Annual MMG and MRI (Minimum age 30 and 25 respectively)
## Germline mutation
### Management per mutation

-----

# Noninvasive Breast Event
## LCIS or ADH
### Chemoprevention with AI or Tamoxifen (20mg vs babytam) IRRESPECTIVE of ER status 
## DCIS
### ER+ve Mastectomy VERSUS BCS → RT → ET
### Adjuvant ET for contralat. chemoPPX. ET should be TAM (Pre) vs AI (Post) vs Tam 5mg PO qD x 3yr
Oncotype DCIS or DecisionRT post BCS can omit RT if low score
### ER-ve Mastectomy VERSUS BCS → RT

-----


# EARLY BREAST CANCER (I, II, III)


## PREMENOPAUSAL HR POSITIVE HER2 NEGATIVE 
### pT1a N0		Definitive Surgery. [Role of ET?]
### pT1b-2 N0	Definitive Surgery → RS (ddAC/TC) → Adjuvant ET [TAM (pre) or AI (post)] x 5 years +/- 5 years (BCI)
### pT1-2 N1	[Consider NACT] Definitive Surgery → RS (ddAC/TC) → Adjuvant ET (Ov Suppression if pre) x 5 years +/- 5 years (BCI)
### pT3-4 N0	[Consider NACT] Definitive Surgery → TC OR ddAC/T [RS NOT validated] → Adjuvant ET x 5 years +/- 5 years (BCI).
### pT3 N1-3	[Consider NACT] Definitive Surgery → ddAC/T [RS NOT validated] → Adjuvant ET (Ov Suppression if pre) x 5 years + 5 years. 
### Based off TAILORx (Node NEG. 2018) RxPONDER (1 to 3 nodes. 2021) 
#### N+ve
##### → Chemotherapy irrespective of RS
#### N-ve 		
##### → RS ≥26: Chemo. 
##### → RS 16-25 : Discuss. 
##### → ≤15 or less → no chemo
### Adjuvant Targeted therapies
#### OLAPARIB in high-risk ER+ HER2- gBRCA1/2 Stage II and III
#### ABEMACICLIB in high risk patient: pN2/3 OR pN1 with either T3 OR Grade III


-----


## POSTMENOPAUSAL HR POSITIVE HER2 NEGATIVE 

### pT1a N0		Definitive Surgery. [Role of ET?]
### pT1b-2 N0	Definitive Surgery → RS (ddAC/TC) → Adjuvant ET [TAM (pre) or AI (post)] x 5 years +/- 5 years (BCI)
### pT1-2 N1	[Consider NACT] Definitive Surgery → RS (ddAC/TC) → Adjuvant ET (Ov Suppression if pre) x 5 years +/- 5 years (BCI)
### pT3-4 N0	[Consider NACT] Definitive Surgery → TC OR ddAC/T [RS NOT validated] → Adjuvant ET x 5 years +/- 5 years (BCI).
### pT3 N1-3	[Consider NACT] Definitive Surgery → ddAC/T [RS NOT validated] → Adjuvant ET (Ov Suppression if pre) x 5 years + 5 years. 
### Based off TAILORx (Node NEG. 2018) RxPONDER (1 to 3 nodes. 2021) 
#### Postmenopausal (Node + or -)	→ RS ≥26: benefited from Chemo regardless of LNs
### Adjuvant Targeted therapies
#### OLAPARIB in high-risk ER+ HER2- gBRCA1/2 Stage II and III
#### ABEMACICLIB in high risk patient: pN2/3 OR pN1 with either T3 OR Grade III

-----

## HR NEGATIVE HER2 POSITIVE
### cT1a N0		Definitive Surgery (Role of Adj Anti HER2?)
### cT1b-1c N0		Definitive Surgery → Weekly Txl/Herceptin (APT) vs H alone (age 75+)
### cT12-4 OR N1-3		Txr/Carbo/Herceptin/Perjeta NACT vs. TDM1/Perjeta → Definitive Surgery
#### No pCR	TDM-1 to complete a year
#### pCR	HP to complete a year

-----

## HR POSITIVE HER2 POSITIVE
### cT1a N0		Definitive Surgery (Role of Adj Anti HER2?)
### cT1b-1c N0		Definitive Surgery → Weekly Txl/Herceptin (APT) vs H alone (age 75+) + TAM/AI/OFS+AI
### cT2-4 OR N1-3		Txr/Carbo/Herceptin/Perjeta NACT vs. TDM1/Perjeta → Definitive Surgery 
#### No pCR	TDM-1 to complete a year + TAM/AI/OFS+AI 
#### pCR	HP to complete a year + TAM/AI/OFS+AI → Neratinib + TAM/AI/OFS+AI

-----

## HR NEGATIVE HER2 NEGATIVE
### cT1a N0		Definitive Surgery (Role of Adj Chemotherapy?)
### cT1b-3 N1-3		NACT Carbo/Txl/Pembro → ddAC / Pembro → Definitive Surgery 
#### No pCR 	Adj. Pembro then Capecitabine (Standard 1250mg/m2 vs Metronomic 600mg/m2)
#### pCR		Adj. Pembro then Metronomic Cape. PARPi if HBOC (if very high risk)
#### PARPi if HBOC

-----


# METASTATIC BREAST CANCER (IV)

## PREMENOPAUSAL HR POSITIVE HER2 NEGATIVE 
Ibrance DID NOT demonstrate Overall Survival in PALOMA2 and PALOMA3. Kisqali and Verzenio are recommended 1st Line agents now
MAINTAIN trial demonstrated benefit in Ribo post Palbo progression
Chemotherapy includes Paclitaxel/ Carbo Gem / Abraxane / Eribulin / Capecitabine / Doxil / Vinorelabine/Ixabepilone
### 1st line
#### OFS+AI+CDK4/6 (Kisqali per MONALEESA-7)

### 2nd line
#### Soft progression → OFS / Faslo / Abema. 
#### PIK3CA mut → OFS / Faslo / Piqray. 
#### ESR1 mut → OFS / Elacestrant
#### HBOC/sBRCA/gPALB2 → PARPi. 
#### Otherwise, OFS / Faslodex/Everolimus vs Enhertu (IHC 1+ or 2+ with Gp5)

### 3rd line
#### Enhertu (IHC 1+ or 2+ with Gp5) OR Chemotherapy
### Further lines	CHEMOTHERAPY
-----

## POSTMENOPAUSAL HR POSITIVE HER2 NEGATIVE 

### 1st line	
#### AI+CDK4/6. Consider holding CDK if low volume. 
### 2nd line
#### Soft progression → Faslo / Abema. 
#### PIK3CA mut → Faslo / Piqray. 
#### ESR1 mut → Elacestrant
#### HBOC/sBRCA/gPALB2 → PARPi. Otherwise, Faslodex/Everolimus
### 3rd line
#### Enhertu (IHC 1+ or 2+ with Gp5) OR Chemotherapy
### Further lines	CHEMOTHERAPY
-----


## HR NEGATIVE HER2 POSITIVE
### 1st line
#### Taxane/HP (vs Tr/HP) → maintenance HP	
### 2nd lin
#### Enhertu vs Cape/Tucatinib/Herceptin 
### 3rd line
#### Enhertu vs Cape/Tucatinib/Herceptin vs Margetuximab vs Cape/Neratinib
### Further lines	CHEMOTHERAPY
-----

## HR POSITIVE HER2 POSITIVE
### 1st line
#### Taxane / HP (vs Tr/HP) → maintenance HP + ET (OFS/AI vs AI)
### 2nd line
#### Enhertu vs Cape/Tucatinib/Herceptin vs Faslo / Abema / H
### 3rd line
#### Enhertu vs Cape/Tucatinib/Herceptin vs Margetuximab vs Cape/Neratinib
### Further lines	CHEMOTHERAPY
-----

## HR NEGATIVE HER2 NEGATIVE
### 1st line
#### Pembro (22C3 +ve) +/- Taxol/Abraxane/CarboGem 
#### Olaparib/Talzaporib (germline BRCA1/BRCA2 OR per TBCRC 048 gPALB2 OR somatic BRCA2)
#### If not NGS, Paclitaxel (3 on 1 off)
#### Capecitabine (Std vs low dose)
#### Taxotere/Cytoxan
### 2nd line
#### Trodelvy
#### Enhertu (IHC 1+ or 2+ with Gp5)
#### CHEMOTHERAPY 
#### Consider Ixabepilone if progression on Adria and Taxane
### 3rd line
#### Trodelvy
#### Enhertu (IHC 1+ or 2+ with Gp5) 
#### CHEMOTHERAPY
#### Consider Halaven if progression on two prior chemotherapy agents
### Further lines	CHEMOTHERAPY

-----


# LOCAL/REGIONAL RECURRENCE
## ER POSITIVE: CALOR demonstrated no benefit in re-administration of Chemotherapy
## ER NEGATIVE: Modest benefit of rechallenge with chemotherapy

-----













SPECIFIC SITUATIONS
Encapsulated Papillary → managed as DCIS
Tubular, Mucinous and Papillary → Adj Endocrine Rx. Add Chemo if pN1a-3
Adenoid Cystic TNBC is associated with favorable prognosis and might not need chemotherapy unless N+ disease
Male BC → 
ER+		Definitive Surgery → TAM (NOT AI alone) Can use AI with GnRH
ER-ve		Definitive Surgery → Chemotherapy (ddAC/T)
Advanced ER+	CDK4/6 + either TAM OR AI/GnRH agonist → Faslodex as 2nd line
Capecitabine. STANDARD 1250mg/m2 D1-14 of 21D CYCLE * 8 CYCLES. METRONOMIC 650mg/m2 D1-28 of 28D CYCLE *12 CYCLES
NACT Carbo/Txl/Pembro might require Neupogen support per weekly basis
Per early HERA trials, EF drop is LVEF ≤ 16% drop from baseline OR ≤ 40%. TTE q3Months while on HP
HP and TDM1 are given to complete 1 full year of AntiHER2 therapy
Per EBCTG, ER3+ 10% to 100% all derive benefit
Per EBCTG, ER- PR+ derive no benefit
Adriamycin is recommended in N2/N3 ER+ OR TNBC
Can Skip RT If >65 ER+ pN0 s/p Mastectomy
Need postop RT if pT3 or pN+